DaVita (DVA) Competitors $138.44 -1.93 (-1.37%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$138.43 -0.01 (-0.01%) As of 08/1/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DVA vs. ALGN, DXCM, HQY, MMSI, CAH, COR, EHC, HAE, ITGR, and MCKShould you be buying DaVita stock or one of its competitors? The main competitors of DaVita include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), Cardinal Health (CAH), Cencora (COR), Encompass Health (EHC), Haemonetics (HAE), Integer (ITGR), and McKesson (MCK). These companies are all part of the "medical" sector. DaVita vs. Its Competitors Align Technology DexCom HealthEquity Merit Medical Systems Cardinal Health Cencora Encompass Health Haemonetics Integer McKesson Align Technology (NASDAQ:ALGN) and DaVita (NYSE:DVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is ALGN or DVA more profitable? Align Technology has a net margin of 11.04% compared to DaVita's net margin of 6.63%. DaVita's return on equity of 176.11% beat Align Technology's return on equity.Company Net Margins Return on Equity Return on Assets Align Technology11.04% 13.36% 8.32% DaVita 6.63%176.11%4.66% Which has more volatility and risk, ALGN or DVA? Align Technology has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, DaVita has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Do institutionals & insiders believe in ALGN or DVA? 88.4% of Align Technology shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.7% of Align Technology shares are held by company insiders. Comparatively, 2.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ALGN or DVA? In the previous week, Align Technology had 49 more articles in the media than DaVita. MarketBeat recorded 60 mentions for Align Technology and 11 mentions for DaVita. DaVita's average media sentiment score of 0.93 beat Align Technology's score of 0.10 indicating that DaVita is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Align Technology 15 Very Positive mention(s) 5 Positive mention(s) 15 Neutral mention(s) 11 Negative mention(s) 7 Very Negative mention(s) Neutral DaVita 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, ALGN or DVA? DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlign Technology$4.00B2.47$421.36M$5.9323.02DaVita$12.82B0.82$936.34M$10.0913.72 Do analysts prefer ALGN or DVA? Align Technology currently has a consensus price target of $215.00, suggesting a potential upside of 57.49%. DaVita has a consensus price target of $167.40, suggesting a potential upside of 20.92%. Given Align Technology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Align Technology is more favorable than DaVita.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Align Technology 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.60DaVita 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryAlign Technology beats DaVita on 10 of the 17 factors compared between the two stocks. Get DaVita News Delivered to You Automatically Sign up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DVA vs. The Competition Export to ExcelMetricDaVitaMED IndustryMedical SectorNYSE ExchangeMarket Cap$10.45B$3.67B$5.53B$20.46BDividend YieldN/A1.38%4.74%3.71%P/E Ratio13.7233.3928.9529.00Price / Sales0.82151.02443.4157.02Price / Cash7.2420.7424.4817.53Price / Book28.664.278.364.53Net Income$936.34M$189.47M$3.25B$994.29M7 Day Performance-4.77%-4.41%-3.55%-3.62%1 Month Performance-2.89%-6.61%5.11%-2.71%1 Year Performance-0.77%-0.57%25.34%10.16% DaVita Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DVADaVita4.418 of 5 stars$138.44-1.4%$167.40+20.9%-0.8%$10.45B$12.82B13.7276,000News CoverageUpcoming EarningsALGNAlign Technology4.9416 of 5 stars$207.19+0.8%$242.92+17.2%-36.1%$15.02B$4.00B37.7420,945Trending NewsEarnings ReportInsider TradeDXCMDexCom4.9727 of 5 stars$89.53+0.6%$98.72+10.3%+9.7%$35.11B$4.03B66.8110,300Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHQYHealthEquity3.7265 of 5 stars$95.76-0.3%$118.55+23.8%+27.5%$8.28B$1.20B69.903,120Positive NewsGap DownMMSIMerit Medical Systems4.556 of 5 stars$84.46-0.3%$109.11+29.2%-4.5%$4.99B$1.39B41.407,400Trending NewsEarnings ReportAnalyst ForecastCAHCardinal Health4.68 of 5 stars$156.27-0.6%$158.07+1.2%+53.5%$37.30B$226.83B24.3848,900News CoveragePositive NewsAnalyst DowngradeCORCencora4.3815 of 5 stars$285.98-1.5%$309.83+8.3%+16.5%$55.43B$293.96B33.1846,000Positive NewsUpcoming EarningsEHCEncompass Health4.8751 of 5 stars$107.10-0.5%$131.50+22.8%+17.2%$10.80B$5.37B22.1340,000HAEHaemonetics4.8116 of 5 stars$74.66-0.7%$97.30+30.3%-16.9%$3.59B$1.36B22.563,023News CoveragePositive NewsUpcoming EarningsITGRInteger3.3493 of 5 stars$108.02-0.5%$140.25+29.8%-4.7%$3.77B$1.79B47.5911,000MCKMcKesson4.5213 of 5 stars$705.86-0.8%$710.17+0.6%+10.8%$88.31B$359.05B27.3345,000News CoveragePositive NewsUpcoming EarningsDividend Increase Related Companies and Tools Related Companies ALGN Competitors DXCM Competitors HQY Competitors MMSI Competitors CAH Competitors COR Competitors EHC Competitors HAE Competitors ITGR Competitors MCK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:DVA) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
